top of page

RESOURCES

Community, compassion, harm reduction, rehabilitation

NON FICTION  

The titles below provide an insight into addiction, treatment and harm reduction:

  • Ingrid van Beek; In the Eye of the Needle - diary of Sydney MSIC

  • Matt Noffs; Breaking the Ice: How We Will Get Through Australia's Methamphetamine Crisis.

  • Johan Hari; Chasing the Scream: The First and Last Days of the War on Drugs. 

  • David Nutt; Drugs - Without the Hot Air: Minimising the Harms of Legal and Illegal Drugs.

​

CORONIAL REPORTS  

The listed Coronial Reports are related to fatal overdoses within the Vic St precinct. 

​

PEER REVIEWED PAPERS

We'd like to thank the Uniting MSIC (Kings Cross) for allowing us to reproduce their list of 110 peer-reviewed papers showing the effectiveness of medically supervised injecting centres.

​

Specific information about the Uniting MSIC (Kings Cross) can be found here

​

Key references

ANDRESEN, M. A. & BOYD, N. 2010. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. International Journal of Drug Policy, 21, 70-76.

​

ANDRESEN, M. A. & JOZAGHI, E. 2012. The point of diminishing returns: an examination of expanding Vancouver’s Insite. Urban Stud, 49, 3531–3544.

​

AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE. 2007. National Drug Strategy household survey: first results. Drug Statistics Series # 20 PHE 98.

​

BAYOUMI, A. & ZARIC, G. 2008. The cost-effectiveness of Vancouver’s supervised injection facility. Can Med Assoc J, 179, 1143-1151.

​

BRAVO, M. J., ROYUELA, L., DE LA FUENTE, L., BRUGAL, M. T., BARRIO, G. & DOMINGO-SALVANY, A. 2009. Use of supervised injection facilities and injection risk behaviours among young drug injectors. Addiction, 104, 6124-9.

​

BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV/AIDS 2009. Findings from the evaluation of Vancouver's Pilot Medically Supervised Safer Injecting Facility - Insite. Vancouver: British Columbia Centre for Excellence in HIV/AIDS.

​

COMMONWEALTH DEPARTMENT OF HEALTH AND AGEING. 2002. Return on investment in needle and syringe programs in Australia. Canberra: Department of Health and Ageing.

​

DEBECK, K., KERR, T., BIRD, L., ZHANG, R., MARSH, D., TYNDALL, M., MONTANER, J. & WOOD, E. 2011. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug and Alcohol Dependence, 113, 172-176.

​

DEBECK, K., WOOD, E., ZHANG, R., TYNDALL, M., MONTANER, J. & KERR, T. 2008. Police and public health partnerships: Evidence from the evaluation of Vancouver's supervised injection facility. Substance Abuse Treatment, Prevention, and Policy, 3, 1-5.

​

DES JARLAIS, D. C., ARASTEH, K. & HAGAN, H. 2008. Evaluating Vancouver’s supervised injection facility: Data and dollars, symbols and ethics. Can Med Assoc J, 179, 1105–1106.

​

DONNELLY, N. & SNOWBALL, L. 2006. Recent trends in property and drug-related crime in Kings Cross. Crime and Justice Bulletin, 105, 1-7.

​

DRUCKER, E. 2006. Insite: Canada's landmark safe injecting program at risk. Harm Reduct Journal, 3(24).

​

FITZGERALD, J., BURGESS, M. & SNOWBALL, L. 2010. Trends in property and illicit drug crime around the Medically Supervised Injecting Centre in Kings Cross: an update. Crime and Justice Statistics, 51, 1-6.

​

FREEMAN, K., JONES, C. G. A., WEATHERBURN, D. J., RUTTER, S., SPOONER, C. J. & DONNELLY, N. 2005. The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug and Alcohol Review, 24, 173-184.

​

HEDRICH, D. 2004. European report on drug consumption rooms. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

​

HEDRICH, D., T., K. & DUBOIS-ARBER, F. 2010. Drug consumption facilites in Europe and beyond. Lisbon: EMCDDA.

HUNT, N. 2006. Indicators of the need for drug consumption rooms in the UK (Paper A). Independent Working Group on Drug Consumption Rooms. York: Joseph Rowntree Foundation.

​

INDEPENDENT WORKING GROUP ON DRUG CONSUMPTION ROOMS. 2006. The report of the independent working group on drug consumption rooms. York: Joseph Rowntree Foundation.

​

JAUNCEY, M., TREVAN, A. P. & SULOVSKY, R. P. 2010. Expecting the unexpected: Intravenous insulin at Sydney's medically supervised injecting centre. MJA, 192, 477.

​

JAUNCEY, M., VAN BEEK, I., AM., S. & MAHER, L. 2011. Bipartisan support for Australia's supervised injecting facility: a decade in the making. MJA, 195, 264.

​

JOINT SELECT COMMITTEE INTO SAFE INJECTING ROOMS. 1998. Report on the establishment or trial of safe injecting rooms. Sydney: Parliament of New South Wales.

​

KERR, T., KIMBER, J., DEBECK, K. & WOOD, E. 2007a. The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Current HIV/AIDS Reports, 4, 158-164.

​

KERR, T., MONTANER, J. & WOOD, E. 2008. Supervised injecting facilities: time for scale-up? Lancet, 372, 354-355.

​

KERR, T., OLESON, M., TYNDALL, M. W., MONTANER, J. & WOOD, E. 2005a. A Description of a Peer-Run Supervised Injection Site for Injection Drug Users. J Urban Health, 82, 267-275.

​

KERR, T., SMALL, W., MOORE, D. & WOOD, E. 2007b. A micro-environmental intervention to reduce the harms associated with drug-related overdose: Evidence from the evaluation of Vancouver's safer injection facility. International Journal of Drug Policy, 18, 37-45.

​

KERR, T., STOLTZ, J., TYNDALL, M., LI, K., ZHANG, R., MONTANER, J. & WOOD, E. 2006a. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. British Medical Journal, 332, 220-222.

​

KERR, T., TYNDALL, M., LAI, C., MONTANER, J. S. G. & WOOD, E. 2006b. Drug-related overdoses within a medically supervised safer injection facility. International Journal of Drug Policy, 17, 436-441.

​

KERR, T., TYNDALL, M., LI, K., MONTANER, J. & WOOD, E. 2005b. Safer injection facility use and syringe sharing in injection drug users. Lancet, 366, 316-318.

​

KERR, T., TYNDALL, M. W., ZHANG, R., LAI, C., MONTANER, J. S. G. & WOOD, E. 2007c. Circumstances of First Injection Among Illicit Drug Users Accessing a Medically Supervised Safer Injection Facility. Am J Public Health, AJPH.2006.086256.

​

KERR, T. & WOOD, E. 2008. Closing the gap between evidence and action: the need for knowledge translation in the field of drug policy research. International Journal of Drug Policy, 19, 233-234.

​

KERR, T., WOOD, E., SMALL, D., PALEPU, A. & TYNDALL, M. W. 2003. Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. Canadian Medical Association Journal, 169, 759-763.

​

KIMBER, J. & DOLAN, K. 2007. Shooting gallery operation in the context of establishing a medically supervised injecting center: Sydney, Australia. Journal of Urban Health, 84, 255-266.

​

KIMBER, J., DOLAN, K., VAN BEEK, I., HEDRICH, D. & ZURHOLD, H. 2003a. Drug consumption facilities: an update since 2000. Drug and Alcohol Review, 22, 227-233.

​

KIMBER, J., HICKMAN, M., DEGENHARDT, L., COULSON, T. & VAN BEEK, I. 2008a. Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. Addiction, 103, 1604-1613.

​

KIMBER, J., MACDONALD, M., VAN BEEK, I., KALDOR, J., WEATHERBURN, D., LAPSLEY, H. & MATTICK, R. P. 2003b. The Sydney Medically Supervised Injecting Centre: client characteristics and predictors of frequent attendance during the first 12 months of operation. Journal of Drug Issues, 33, 639-648.

​

KIMBER, J., MATTICK, R. P., KALDOR, J., VAN BEEK, I., GILMOUR, S. & RANCE, J. A. 2008b. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug and Alcohol Review, 27, 602-612.

​

KPMG. 2010. Further Evaluation of the Medically Supervised Injecting Centre during its extended trial period (2007-2011): Final Report. Sydney KPMG.

​

MAHER, L. & SALMON, A. M. 2007. Supervised injecting facilities: how much evidence is enough? Drug and Alcohol Review, 26, 351-353.

​

MARSHALL, B. D., MILLOY, M. J., WOOD, E., MONTANER, J. S. & KERR, T. 2011. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet, 377, 1429-37.

​

MARSHALL, B. D. L., WOOD, E., ZHANG, R., TYNDALL, M. W., MONTANER, J. S. G. & KERR, T. 2009. Condom use among injection drug users accessing a supervised injecting facility. Sexually transmitted infections, 85, 121-126.

​

MATTHEW-SIMMONS, F., LOVE, S. & RITTER, A. 2008. A review of Australian public opinion surveys on illicit drugs. Monograph No. 17, Sydne, National Drug and Alcohol Research Centre. DPMP Monograph Series.

​

MCKNIGHT, I., MAAS, B., WOOD, E., TYNDALL, M. W., SMALL, W., LAI, C., MONTANER, J. S. G. & KERR, T. 2007. Factors associated with public injecting among users of Vancouver's supervised injection facility. The American Journal of Drug and Alcohol Abuse, 33, 319-325.

​

MILLOY, M.-J., KERR, T., MATHIAS, R., ZHANG, R., MONTANER, J. S., TYNDALL, M. & WOOD, E. 2008a. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. The American journal of drug and alcohol abuse, 34, 499-509.

​

MILLOY M.J. & E., W. 2009. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction, 104, 620-1.

​

MILLOY, M. J. S., KERR, T., TYNDALL, M., MONTANER, J. & WOOD, E. 2008b. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS ONE, 3, e3351.

​

MSIC EVALUATION COMMITTEE. 2003. Final report of the evaluation of the Sydney Medically Supervised Injecting Centre. Sydney: Authors.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2005. Sydney Medically Supervised Injecting Centre Interim Report 1: operations and service delivery (November 2002 to December 2004). Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2006. Sydney Medically Supervised Injecting Centre Interim Report 2: evaluation of community attitudes towards the Sydney MSIC. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2007a. Sydney Medically Supervised Injecting Centre Evaluation Report 4: evaluation of service operation and overdose-related events. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2007b. Sydney Medically Supervised Injecting Centre Interim Evaluation Report 3: evaluation of client referral and health issues. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

PETRAR, S., KERR, T., TYNDALL, M. W., ZHANG, R., MONTANER, J. S. & WOOD, E. 2007. Injection drug users' perceptions regarding use of a medically supervised safer injecting facility. Addictive Behaviors, 32, 1088 - 1093.

​

PINKERTON, S. D. 2010. Is Vancouver Canada's supervised injection facility cost-saving? Addiction, 105, 1429-1436.

​

PINKERTON, S. D. 2011. How many HIV infections are prevented by Vancouver Canada's supervised injection facility? International Journal of Drug Policy, 22, 179-183.

​

RICHARDSON, L., WOOD, E., ZHANG, R., MONTANER, J., TYNDALL, M. & KERR, T. 2008. Employment Among Users of a Medically Supervised Safer Injection Facility. American Journal of Drug and Alcohol Abuse, 34, 519-525.

​

SAHA INTERNATIONAL LIMITED. 2008. Final report: economic evaluation of the Medically Supervised Injecting Centre at Kings Cross (MSIC).

​

SALMON AM, T. H.-H., KIMBER J, KALDOR JM, MAHER L. 2007. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? . International Journal of Drug Policy 18.

​

SALMON, A. M., VAN BEEK, I., AMIN, J., KALDOR, J. & MAHER, L. 2010. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction, 105, 676-683.

​

SEMAAN, S., FLEMING, P., WORRELL, C., STOLP, H., BAACK, B. & MILLER, M. 2011. Potential role of safer injection facilities in reducing HIV and Hepatitis C infections and overdose mortality in the United States. Drug Alcohol Depend, 118, 100-110.

​

SNOWBALL, L., BURGESS, M. & PRICE, B. 2008. Trends in property and illicit drug-related crime in Kings Cross: An update, NSW Bureau of Crime Statistics and Research Sydney.

​

STOLTZ, J., WOOD, E., SMALL, W., LI, K., TYNDALL, M., MONTANER, J. & KERR, T. 2007a. Changes in injecting practices associated with the use of a medically supervised safer injection facility. Journal of Public Health, 29, 35-39.

​

STOLTZ, J. M., WOOD, E., MILLER, C., SMALL, W., LI, K., TYNDALL, M., MONTANER, J. & KERR, T. 2007b. Characteristics of young illicit drug injectors who use North America's first medically supervised safer injecting facility. Addiction Research & Theory, 15, 63-69.

​

STRATHDEE, S. A. & POLLINI, R. 2007. A 21st century Lazarus: the role of safer injecting sites in harm reduction and recovery. Addiction, 102, 848-849.

​

THEIN, H.-H., KIMBER, J., MAHER, L., MACDONALD, M. & KALDOR, J. 2005. Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy, 16, 275-280.

​

VAN BEEK, I. 2003. The Sydney Medically Supervised Injecting Centre: a clinical model. Journal of Drug Issues, 33, 625-638.

​

VAN BEEK, I., KIMBER, J., DAKIN, A. & GILMOUR, S. 2004. The Sydney Medically Supervised Injecting Centre: reducing harm associated with heroin overdose. Critical Public Health, 14, 391-406.

​

WOOD, E., KERR, T., LLOYD-SMITH, E., BUCHNER, C., MARSH, D., MONTANER, J. S. & TYNDALL, M. 2004a. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduction Journal, 1, 9-13.

​

WOOD, E., KERR, T., MONTANER, J. S., STRATHDEE, S. A., WODAK, A., HANKINS, C. A., SCHECHTER, M. T. & TYNDALL, M. W. 2004b. Rationale for evaluating North America's first medically supervised safer injecting facility. Lancet Infect Dis, 4, 301 - 306.

​

WOOD, E., KERR, T., SMALL, W., LI, K., MARSH, D. C., MONTANER, J. S. G. & TYNDALL, M. W. 2004c. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Canadian Medical Association Journal 171, 731-734.

​

WOOD, E., TYNDALL, M., LAI, C., MONTANER, J. & KERR, T. 2006a. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Substance Abuse Treatment, Prevention, and Policy, 1, 1-4.

​

WOOD, E., TYNDALL, M., MONTANER, J. & KERR, T. 2006b. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. Canadian Medical Association Journal, 175, 1399-1404.

​

WOOD, E., TYNDALL, M., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2007. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction, 102, 916-919.

​

WOOD, E., TYNDALL, M., ZHANG, R., STOLTZ, J., LAI, C., MONTANER, J. G. S. & KERR, T. 2006c. Attendance at supervised injecting facilities and use of detoxification services. New England Journal of Medicine, 354, 2512 - 2514.

​

WOOD, E., TYNDALL, M. W., QUI, Z., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2006d. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health, 96, 770-773.

​

WOOD, E., TYNDALL, M. W., STOLTZ, J., SMALL, W., LLOYD-SMITH, E., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2005. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. American Journal of Infectious Diseases, 1, 50-54

​

WRIGHT, N. M. J. & TOMPKINS, C. N. E. 2004. Supervised injecting centres. British Medical Journal, 2004, 100-102.

ZOBEL, F. & DUBOIS-ARBER, F. 2004. Short appraisal of the role and usefulness of Drug consumption facilities (DCF) in the reduction of drug-related problems in Switzerland: appraisal produced at the request of the Swiss Federal Office of Public Health. Lausanne:: University Institute of Social and Preventive Medicine.

​

ZURHOLD, H., DEGKWITZ, P., VERTHEIN, U. & HAASEN, C. 2003. Drug consumption rooms in Hamburg, Germany: evaluation of the effects on harm reduction and the reduction of public nuisance. Journal of Drug Issues, 33, 663-688.

Main Uniting MSIC reports

​

JOINT SELECT COMMITTEE INTO SAFE INJECTING ROOMS. 1998. Report on the establishment or trial of safe injecting rooms. Sydney: Parliament of New South Wales.

​

MSIC EVALUATION COMMITTEE. 2003. Final report of the evaluation of the Sydney Medically Supervised Injecting Centre. Sydney: Authors.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2005. Sydney Medically Supervised Injecting Centre Interim Report 1: operations and service delivery (November 2002 to December 2004). Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2006. Sydney Medically Supervised Injecting Centre Interim Report 2: evaluation of community attitudes towards the Sydney MSIC. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2007a. Sydney Medically Supervised Injecting Centre Evaluation Report 4: evaluation of service operation and overdose-related events. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

NATIONAL CENTRE IN HIV EPIDEMIOLOGY AND CLINICAL RESEARCH. 2007b. Sydney Medically Supervised Injecting Centre Interim Evaluation Report 3: evaluation of client referral and health issues. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

​

SAHA INTERNATIONAL LIMITED. 2008. Final report: economic evaluation of the Medically Supervised Injecting Centre at Kings Cross (MSIC).

​

KPMG. 2010. Further Evaluation of the Medically Supervised Injecting Centre during its extended trial period (2007-2011): Final Report. Sydney KPMG.

​

Main Uniting MSIC papers

JAUNCEY, M., TREVAN, A. P. & SULOVSKY, R. P. 2010. Expecting the unexpected: Intravenous insulin at Sydney's medically supervised injecting centre. MJA, 192, 477.

​

JAUNCEY, M., VAN BEEK, I., AM., S. & MAHER, L. 2011. Bipartisan support for Australia's supervised injecting facility: a decade in the making. MJA, 195, 264.

​

KIMBER, J., DOLAN, K., VAN BEEK, I., HEDRICH, D. & ZURHOLD, H. 2003. Drug consumption facilities: an update since 2000. Drug and Alcohol Review, 22, 227-233.

​

KIMBER, J., HICKMAN, M., DEGENHARDT, L., COULSON, T. & VAN BEEK, I. 2008a. Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. Addiction, 103, 1604-1613.

​

KIMBER, J., MATTICK, R. P., KALDOR, J., VAN BEEK, I., GILMOUR, S. & RANCE, J. A. 2008b. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug and Alcohol Review, 27, 602-612.

​

MAHER, L. & SALMON, A. M. 2007. Supervised injecting facilities: how much evidence is enough? Drug and Alcohol Review, 26, 351-353.

​

SALMON AM, T. H.-H., KIMBER J, KALDOR JM, MAHER L. 2007. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? . International Journal of Drug Policy 18.

​

SALMON, A. M., VAN BEEK, I., AMIN, J., KALDOR, J. & MAHER, L. 2010. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction, 105, 676-683.

​

THEIN, H.-H., KIMBER, J., MAHER, L., MACDONALD, M. & KALDOR, J. 2005. Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy, 16, 275-280.

​

VAN BEEK, I. 2003. The Sydney Medically Supervised Injecting Centre: a clinical model. Journal of Drug Issues, 33, 625-638.

​

VAN BEEK, I., KIMBER, J., DAKIN, A. & GILMOUR, S. 2004. The Sydney Medically Supervised Injecting Centre: reducing harm associated with heroin overdose. Critical Public Health, 14, 391-406.

​

Crime

DEBECK, K., WOOD, E., ZHANG, R., TYNDALL, M., MONTANER, J. & KERR, T. 2008. Police and public health partnerships: Evidence from the evaluationof Vancouver's supervised injection facility. Substance Abuse Treatment, Prevention, and Policy, 3, 1-5.

​

DONNELLY, N. & SNOWBALL, L. 2006. Recent trends in property and drug-related crime in Kings Cross. Crime and Justice Bulletin, 105, 1-7.

​

FITZGERALD, J., BURGESS, M. & SNOWBALL, L. 2010. Trends in property and illicit drug crime around the Medically Supervised Injecting Centre in Kings Cross: an update. Crime and Justice Statistics, 51, 1-6.

​

FREEMAN, K., JONES, C. G. A., WEATHERBURN, D. J., RUTTER, S., SPOONER, C. J. & DONNELLY, N. 2005. The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug and Alcohol Review, 24, 173-184.

​

SNOWBALL, L., BURGESS, M. & PRICE, B. 2008. Trends in property and illicit drug-related crime in Kings Cross: An update, NSW Bureau of Crime Statistics and Research Sydney.

​

WOOD, J.R.T. 1997. Royal commission into the New South Wales Police Service: Final report (Volume II: Reform).

Economic evaluation

​

ANDRESEN, M. A. & BOYD, N. 2010. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. International Journal of Drug Policy, 21, 70-76.

​

ANDRESEN, M. A. & JOZAGHI, E. 2012. The point of diminishing returns: an examination of expanding Vancouver’s Insite. Urban Stud, 49, 3531–3544.

​

BAYOUMI, A. & ZARIC, G. 2008. The cost-effectiveness of Vancouver’s supervised injection facility. Can Med Assoc J, 179, 1143-1151.

​

COMMONWEALTH DEPARTMENT OF HEALTH AND AGEING. 2002. Return on investment in needle and syringe programs in Australia. Canberra: Department of Health and Ageing;.

​

DES JARLAIS, D. C., ARASTEH, K. & HAGAN, H. 2008. Evaluating Vancouver’s supervised injection facility: Data and dollars, symbols and ethics. Can Med Assoc J, 179, 1105–1106.

​

PINKERTON, S. D. 2010. Is Vancouver Canada's supervised injection facility cost-saving? Addiction, 105, 1429-1436.

​

PINKERTON, S. D. 2011. How many HIV infections are prevented by Vancouver Canada's supervised injection facility? International Journal of Drug Policy, 22, 179-183.

​

RICHARDSON, L., WOOD, E., ZHANG, R., MONTANER, J., TYNDALL, M. & KERR, T. 2008. Employment Among Users of a Medically Supervised Safer Injection Facility. American Journal of Drug and Alcohol Abuse, 34, 519-525.

​

SAHA INTERNATIONAL LIMITED. 2008. Final report: economic evaluation of the Medically Supervised Injecting Centre at Kings Cross (MSIC).

​

Insite

BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV/AIDS 2009. Findings from the evaluation of Vancouver's Pilot Medically Supervised Safer Injecting Facility - Insite. Vancouver: British Columbia Centre for Excellence in HIV/AIDS.

​

DEBECK, K., KERR, T., BIRD, L., ZHANG, R., MARSH, D., TYNDALL, M., MONTANER, J. & WOOD, E. 2011. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug and Alcohol Dependence, 113, 172-176.

​

DEBECK, K., WOOD, E., ZHANG, R., TYNDALL, M., MONTANER, J. & KERR, T. 2008. Police and public health partnerships: Evidence from the evaluationof Vancouver's supervised injection facility. Substance Abuse Treatment, Prevention, and Policy, 3, 1-5.

​

DRUCKER, E. 2006. Insite: Canada's landmark safe injecting program at risk. Harm Reduct Journal, 3(24).

KERR, T., KIMBER, J., DEBECK, K. & WOOD, E. 2007. The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Current HIV/AIDS Reports, 4, 158-164.

​

KERR, T., STOLTZ, J., TYNDALL, M., LI, K., ZHANG, R., MONTANER, J. & WOOD, E. 2006. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. British Medical Journal, 332, 220-222.

​

KERR, T., TYNDALL, M., LI, K., MONTANER, J. & WOOD, E. 2005. Safer injection facility use and syringe sharing in injection drug users. Lancet, 366, 316-318.

​

MCKNIGHT, I., MAAS, B., WOOD, E., TYNDALL, M. W., SMALL, W., LAI, C., MONTANER, J. S. G. & KERR, T. 2007. Factors associated with public injecting among users of Vancouver's supervised injection facility. The American Journal of Drug and Alcohol Abuse, 33, 319-325.

​

MARSHALL, B. D., MILLOY, M. J., WOOD, E., MONTANER, J. S. & KERR, T. 2011. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet, 377, 1429-37.

​

MILLOY, M. J. S., KERR, T., TYNDALL, M., MONTANER, J. & WOOD, E. 2008b. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS ONE, 3, e3351.

​

PETRAR, S., KERR, T., TYNDALL, M. W., ZHANG, R., MONTANER, J. S. & WOOD, E. 2007. Injection drug users' perceptions regarding use of a medically supervised safer injecting facility. Addictive Behaviors, 32, 1088 - 1093.

​

STOLTZ, J., WOOD, E., SMALL, W., LI, K., TYNDALL, M., MONTANER, J. & KERR, T. 2007a. Changes in injecting practices associated with the use of a medically supervised safer injection facility. Journal of Public Health, 29, 35-39.

​

STOLTZ, J. M., WOOD, E., MILLER, C., SMALL, W., LI, K., TYNDALL, M., MONTANER, J. & KERR, T. 2007b. Characteristics of young illicit drug injectors who use North America's first medically supervised safer injecting facility. Addiction Research & Theory, 15, 63-69.

​

WOOD, E., KERR, T., LLOYD-SMITH, E., BUCHNER, C., MARSH, D., MONTANER, J. S. & TYNDALL, M. 2004a. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduction Journal, 1, 9-13.

​

WOOD, E., KERR, T., MONTANER, J. S., STRATHDEE, S. A., WODAK, A., HANKINS, C. A., SCHECHTER, M. T. & TYNDALL, M. W. 2004b. Rationale for evaluating North America's first medically supervised safer injecting facility. Lancet Infect Dis, 4, 301 - 306.

​

WOOD, E., KERR, T., SMALL, W., LI, K., MARSH, D. C., MONTANER, J. S. G. & TYNDALL, M. W. 2004c. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Canadian Medical Association Journal 171, 731-734.

​

WOOD, E., TYNDALL, M., LAI, C., MONTANER, J. & KERR, T. 2006a. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Substance Abuse Treatment, Prevention, and Policy, 1, 1-4.

​

WOOD, E., TYNDALL, M., MONTANER, J. & KERR, T. 2006b. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. Canadian Medical Association Journal, 175, 1399-1404.

​

WOOD, E., TYNDALL, M., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2007. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction, 102, 916-919.

​

WOOD, E., TYNDALL, M., ZHANG, R., STOLTZ, J., LAI, C., MONTANER, J. G. S. & KERR, T. 2006c. Attendance at supervised injecting facilities and use of detoxification services. New England Journal of Medicine, 354, 2512 - 2514.

​

WOOD, E., TYNDALL, M. W., QUI, Z., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2006d. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health, 96, 770-773.

​

WOOD, E., TYNDALL, M. W., STOLTZ, J., SMALL, W., LLOYD-SMITH, E., ZHANG, R., MONTANER, J. S. G. & KERR, T. 2005. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. American Journal of Infectious Diseases, 1, 50-54

​

International drug consumption rooms

HEDRICH, D. 2004. European report on drug consumption rooms. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

​

HEDRICH, D., T., K. & DUBOIS-ARBER, F. 2010. Drug consumption facilites in Europe and beyond. Lisbon: EMCDDA.

HUNT, N. 2006. Indicators of the need for drug consumption rooms in the UK (Paper A). Independent Working Group on Drug Consumption Rooms. York: Joseph Rowntree Foundation.

​

INDEPENDENT WORKING GROUP ON DRUG CONSUMPTION ROOMS. 2006. The report of the independent working group on drug consumption rooms. York: Joseph Rowntree Foundation.

​

MILLOY, M. J. S., KERR, T., TYNDALL, M., MONTANER, J. & WOOD, E. 2008b. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS ONE, 3, e3351.

​

WRIGHT, N. M. J. & TOMPKINS, C. N. E. 2004. Supervised injecting centres. British Medical Journal, 2004, 100-102.

​

ZOBEL, F. & DUBOIS-ARBER, F. 2004. Short appraisal of the role and usefulness of Drug consumption facilities (DCF) in the reduction of drug-related problems in Switzerland: appraisal produced at the request of the Swiss Federal Office of Public Health. Lausanne:: University Institute of Social and Preventive Medicine.

​

ZURHOLD, H., DEGKWITZ, P., VERTHEIN, U. & HAASEN, C. 2003. Drug consumption rooms in Hamburg, Germany: evaluation of the effects on harm reduction and the reduction of public nuisance. Journal of Drug Issues, 33, 663-688.

bottom of page